Molecular imaging 'probes' pinpoint prostate cancer

June 07, 2010

SALT LAKE CITY--Molecular imaging has a powerful new weapon in the fight against prostate cancer. Research introduced at SNM's 57th Annual Meeting demonstrates how a novel peptide-targeted imaging agent could help clinicians detect a biological process that signals cancer in prostate cells. Information gathered about this process may even differentiate prostate tumor types and the progression of disease.

"This new molecular imaging tool will help us develop new diagnostic and therapeutic options for prostate cancer patients," said Chiun-Wei Huang, Ph.D. candidate, lead author and researcher at the Molecular Imaging Center of the Keck School of Medicine, University of Southern California, Los Angeles, Calif. "By identifying a signature on the cell-surface of specific tumor types at different stages, we could potentially develop better and more customized treatments for truly personalized medicine."

In this study, researchers used near-infrared fluorescent imaging, an optical imaging technique that images the low-frequency light emitted from an imaging agent containing fluorescent dye. The novel agent used in the study was prepared with a peptide that targets receptor activity involved in the prolific growth of certain tumor cells. This specific sequence of receptor activity is called α2β1 integrin, an expression of building-block proteins such as collagen. Cells that display an abnormal over-abundance of this activity could be cancerous, and imaging that focuses on this biological process could provide essential information about the aggressive growth, survival, migration and invasiveness of individual cases of prostate cancer.

Results of the study showed that high absorption of the peptide-targeted agent positively identified prostate tumors both in the laboratory and in three prostate tumor-bearing models. Further development of this and similar imaging agents could lead to more effective and detailed diagnosis of prostate cancer and could be used to test the effectiveness of new drug therapies to treat the disease.
According to the American Cancer Society, prostate cancer is the leading cancer diagnosis in men besides skin cancer. About 1 in 6 men are expected to be diagnosed with prostate cancer at some point in their lives. More than 192,000 men in America were estimated to be diagnosed with prostate cancer in 2009, and 27,360 deaths were projected as a result of the disease.

Scientific Paper 4: C. Huang, Z. Li, H. Cai, A.H. Shahinian, P.S. Conti, University of Southern California, Los Angeles, Calif., "Near-infrared fluorescent imaging of prostate cancer using integrin α2β1 targeted peptide probes," SNM's 57th Annual Meeting, June 5𔃇, 2010, Salt Lake City, Utah.

About SNM--Advancing Molecular Imaging and Therapy

SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.

SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit

Society of Nuclear Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to